Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target
Scrip
|
February 7, 2024
X min read
Scrip
|
February 7, 2024
Share on Social
More like this
News
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Read Now
Press
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Read Now
News
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
September 9, 2025
Read Now
Press
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
September 9, 2025
Read Now
